<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of report (Date of earliest event reported): January 6, 2001
GILEAD SCIENCES, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 0-19731 94-3047598
(State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
</TABLE>
333 Lakeside Drive,
Foster City, CA 94404
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 574-3000
<PAGE>
Item 5. OTHER EVENTS
On January 6, 2001, Gilead Sciences, Inc. entered into a
licensing agreement with Cubist Pharmaceuticals, Inc. for the exclusive
rights to commercialize Cubist's investigational antibacterial drug
Cidecin(TM) (daptomycin for injection) and an oral formulation of
daptomycin in 16 Euriopean countries following regulatory approval. A
press release relating to the agreement is attached hereto as Exhibit
99.1.
Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
EXHIBITS
(c) Exhibits
99.1 Press Release dated January 7, 2001
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GILEAD SCIENCES, INC.
Dated: January 11, 2001 By: /s/ JOHN C. MARTIN
--------------------------------
John C. Martin
President and
Chief Executive Officer
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description
------ -----------
<S> <C>
99.1 Press Release titled "Cubist Pharmaceuticals and Gilead
Sciences Announce European Commercialization Agreement for
Investigational Antibacterial Agent Cidecin" dated January 7,
2001.
</TABLE>
